1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Pricing Transparency Policies Not Suited To Generics, GPhA Argues

 
• By Cathy Kelly

Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.

PharmacyReceipt-Dollars-PillBottles_1200x675

Drug pricing transparency proposals like the recently-introduced bipartisan bill requiring public justification for increases of 10% or more should not target the generic drug sector, Generic Pharmaceutical Association President and CEO Chip Davis says.

Price increases for most generic drugs aren’t moving the needle in overall drug spending, and so federal action to restrain increases are not needed for them, Davis maintained during an...

Findings from GPhA's 2016 Report on Drug Savings and Access in the US
  • Generics produced $227bn in savings in the US
  • Savings to Medicare totaled $67.6bn
  • Savings to Medicaid totaled $32.7bn
  • Generics made up 89% of Rxs dispensed but only...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 
• By Francesca Bruce

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.

More from Market Access

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.